On Nov 07, major Wall Street analysts update their ratings for $Globus Medical (GMED.US)$, with price targets ranging from $85 to $100.
Barclays analyst Matt Miksic maintains with a buy rating, and maintains the target price at $100.
Wells Fargo analyst Vik Chopra maintains with a buy rating, and maintains the target price at $88.
Needham analyst David Saxon maintains with a hold rating.
Stifel analyst Mathew Blackman maintains with a buy rating, and adjusts the target price from $80 to $92.
Piper Sandler analyst Matthew O'Brien maintains with a buy rating, and adjusts the target price from $80 to $100.
Furthermore, according to the comprehensive report, the opinions of $Globus Medical (GMED.US)$'s main analysts recently are as follows:
Globus Medical is poised to resume mid-to-high single-digit sales growth and achieve mid-30's EBITDA margins. The company's earnings outperformance is seen as 'impressive,' driven by robust sales and increasing cost synergies.
Globus Medical has exceeded expectations by continuing to deliver improved financial results, surpassing earlier projections. This success is partly due to the more efficient than anticipated integration of NuVasive, and as a result, there is a belief that better integration execution and enhanced profitability justify a less discounted multiple. Nonetheless, there is a view that realizing cross-selling synergies may prove challenging, particularly in the face of new competitors in the spine robot market entering this quarter, which could pose a challenge in meeting the market's anticipated 7% growth.
Q3 served as a significant confirmation of the thesis that the business has stronger foundations today than most anticipated. It is believed that current estimates may be too conservative and there is potential for a 1-2 turn increase in the multiple.
The company reported strong Q3 results, with sales and EPS exceeding expectations by 3% and 27%, respectively. This marks the fourth consecutive quarter of positive performance following the acquisition of Nuvasive, and due to management's exceptional execution, the company has achieved what is considered the most successful spine merger in the industry.
Globus Medical is challenging the commonly held beliefs about the inefficacy of spine mergers through its recent performance. The company's strict financial discipline and operational execution are contributing to a momentum that is expected to generate substantial free cash flow conversion, which could potentially lead to significant share repurchase activities.
Here are the latest investment ratings and price targets for $Globus Medical (GMED.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$Globus Medical (GMED.US)$的評級，目標價介於85美元至100美元。
巴克萊銀行分析師Matt Miksic維持買入評級，維持目標價100美元。
富國集團分析師Vik Chopra維持買入評級，維持目標價88美元。
Needham分析師David Saxon維持持有評級。
斯迪富分析師Mathew Blackman維持買入評級，並將目標價從80美元上調至92美元。
派傑投資分析師Matthew O'Brien維持買入評級，並將目標價從80美元上調至100美元。
此外，綜合報道，$Globus Medical (GMED.US)$近期主要分析師觀點如下：
globus medical準備恢復中至高個位數的營收增長，並實現30%左右的EBITDA利潤率。公司的盈利表現被視爲'impressive'，推動力來自強勁的銷售和逐漸增加的成本協同效應。
globus medical通過持續提供改善的財務業績，超越先前預期，超額完成預期，引發了市場的關注。這一成功部分歸因於與NuVasive的整合比預期要高效，因此人們認爲更好的整合執行和增強的盈利能力證明出多重估值被低估。儘管如此，仍有看法認爲實現跨銷售協同效應可能會有挑戰，特別是在本季度新競爭對手進入脊柱機器人市場的情況下，這可能對滿足市場預期的7%增長構成挑戰。
第三季度可視爲印證本公司業務比大多數人預期的更加堅實的論點。有人認爲目前的估值可能過於保守，有潛力使出多次的增長。
公司報告的第三季度業績強勁，銷售額和每股收益分別超出預期3%和27%。這標誌着在收購NuVasive後連續第四個季度取得積極業績，由於管理層的出色執行，公司已取得被認爲是行業內最成功的脊柱合併。
globus medical通過最近的業績對脊椎合併的無效性通常觀念提出了挑戰。公司嚴格的財務紀律和運營執行正促使形成有望產生可觀自由現金流轉換的勢頭，這可能導致大規模股票回購活動。
以下爲今日6位分析師對$Globus Medical (GMED.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
